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A. THESE ITEMS ARE REQUIRED FOR REVISIONS
--A letter addressing the reviewers' comments point by point.
--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://life-sciencealliance.org/authorguide --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://life-sciencealliance.org/authorguide We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files. ***IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.***
---------------------------------------------------------------------------
Reviewer #1 (Comments to the Authors (Required)):
In this manuscript, G. Bertolet and colleagues investigate the functional consequences of mutating the 3´-most sequence of miR-146a, without changing the seed nor the central region. Because conflicting data has been published regarding the contribution of non-seed regions, it is indeed important to probe the consequences of such a mutation (especially when the tested phenotypes include in vivo, integrated readouts, as is the case here). The authors find that the mutation triggers some consequences at the microscopic level (when the readout is a target RNA or protein abundance), but they did not find any convincing proof for macroscopic consequences. This is an interesting manuscript, addressing an important question in the field of miRNA-mediated gene regulation. The detailed phenotypic assessment (including many physiological assays, interrogating both homozygous and hemizygous mutants) is exemplary. Several problems (two major points, which seem to affect the authors' interpretations; but also many minor points, which make the manuscript obscure or inconsistent on a few important issues) tend to weaken its conclusions, so I recommend correcting all these points. Once this is done, the manuscript will be a strong candidate for publication in Life Science Alliance.
Major points:
1. Page 5, sentence "Transfection of this vector into HEK 293 cells [...] ": to me, Fig. 1A does not support such a conclusion. It is not exactly clear to me what the authors mean with "similarly processed". Do they imply that the mutant miRNA is matured from Drosha and Dicer cleavages occurring at the same positions? If yes, that poorly-resolved Northern blot, showing smeary bands on two distinct membranes (none of them containing a size marker), does not provide enough information on miRNA length to conclude anything (not even mentioning the fact that miRNAs can have the same length but not the same 5´ and 3´ ends). Or do the authors mean that the mutant miRNA accumulates at the same level than the wt miRNA? If yes, these two membranes, hybridized with two different probes, are also useless for such a conclusion. It is actually possible to use Nothern blot for such an assessment, but then each membrane has to be calibrated with synthetic RNA oligos in a few additional lanes, in order to convert Northern blot intensity signals into fmol of RNA (apparently Fig. 1G used calibrating synthetic oligos: these very same oligos could be used to make a Northern blot really quantitative for Fig. 1A ).
2. Page 28: Fig. 1H compares WT to 3´F in the left panel, and WT to KO in the right panel. Why are the WT histograms so different between the two panels? This is not just a normalization issue, because even the ratios between samples are clearly different (e.g., compare thymus to spleen in both panels). It may be that the PCR-based quantification is not that precise (that would be perfectly understandable), or that there is a lot of biological variability between the batches of mice. But then, why are the s.e.m. so narrow? Whether there is a lot of technical noise, or a lot of biological variability, this should also reflect in the s.e.m. error bars... In the end, if WT replicates are so poorly reproducible, then the whole assay may not be able to detect efficiently any potential difference between WT and 3´F miRNAs. The Chi et al. paper is certainly not very precise regarding the number and identity of CLIP-identified miRNA targets, which does not ease comparison to computational predictions -but at least their number of targets per miRNA, and the high percentage of seedless targets they found, seem to argue against such an optimistic affirmation. Please justify that sentence.
2. Page 3, sentence "This notion would partially explain the strict evolutionary conservation [...]". Another phenomenon seems to explain equally well the conservation of non-seed sequences: because miRNA*s seem to be under a selective pressure to repress seed-matched transcripts (see https://www.ncbi.nlm.nih.gov/pubmed/21177881). As the pre-miRNA secondary structure (hairpinshaped) is also conserved, then the miRNA sequence facing the miRNA* seed has to be conserved -implying that the miRNA 3´ end should be conserved even if it did not play any function in miRNA target recognition.
3. Page 4: for the sake of clarity, the sequence of wild-type and 3´F miR-146a should be given in a main figure (they are currently given in supplementary figure 2, which does not make it easy for the reader to see them while reading the manuscript). Also: the justification of the choice of the mutant sequence (nt 13-20 being AAGUGUCC instead of UCCAUGGG) is very obscure (what is an "anticomplementary sequence"? I know what a "complementary sequence" is, I know what an "antisense sequence" is -and these are the same thing; but an "anti-complementary sequence" is very mysterious to me; at least I can see that it is not the complementary sequence of the wild-type 13-20 subsequence). Please detail.
4. Page 6, sentence "Absolute expression of the mature [...]": Fig. 1H shows some large differences in wt vs. mutant miRNA abundance in at least two samples (kidney and CD8+), so the text should read "in most tissues and cell populations examined", not "all tissues and cell populations". 5. Page 7, sentence "However, none of these phenotypes [...]": please define "aged" mice (the next sentence clearly defines what an "extremely advanced age" is: please do the same here).
6. Page 10, sentence "Because RNA-interference in mammals can mediate [...]". I know there is sometimes much confusion about that term in the literature, but note that "RNA interference" is different from the "miRNA pathway". RNA interference is a sequence-specific repression triggered by a double-stranded RNA (which is converted into siRNAs by Dicer).
7. Page 22, sentence "For comparisons between two groups, [...]": is the assumption of equal variances always justified throughout the manuscript? (in other words: have the authors checked for variance homogeneity?) 8. Page 28, Fig. 1E : maybe it's just an image resolution issue, but: I can't see a WT band for the "miR-146a +/3´F lane" (second from last), while I was expecting one. Anything wrong with that sample? 9. Page 28, Fig. 1D : how can we be sure that the band shown with an asterisk is really due to crosshybridization? If there is no argument supporting it, it should be flagged as "probable" crosshybridizing band.
10. Page 33, Fig. 5E and 5F: in Fig. 5F , the y-axis title reads "Relative IRAK1". Relative to what? Multiple normalization procedures can be imagined here (relative to "-LPS" or not; relative to GAPDH or not), and the legend does not help much. Understanding how exactly the data has been processed would help the reader understand why panel F seems to contradict panel E (which shows clear differences in "-LPS" signals across genotypes). Also, please explain why there are two lanes in each experimental condition for Fig. 5E (two lanes for "WT -LPS", two lanes for "WT +LPS", ...): are these biological duplicates? Then the s.e.m. shown in Fig. 1F would probably be much larger. I am a bit puzzled by these two panels.
11. Page 36, Fig. 7 : what are the "Controls" shown in the rightmost region of both panels (A and B)? They come after a list of gene names, so I guess these are control UTRs, but then why would they respond to the wt miRNA? Please improve the legend.
Reviewer #2 (Comments to the Authors (Required)):
The manuscript by Bertolet et al, studies the role of miRNA 3' pairing in vivo in a mammalian system. In fact, although the seed sequence of a miRNA is usually sufficient and necessary for silencing, some recent studies have proposed a role for the sequence beyond the seed in mammalian cells and C. elegans. To investigate the role of 3' pairing in vivo in mammalian system, the authors studied miR-146a, whose deletion was already shown to induce several immune defects. Specifically, they generated a mouse harboring a mutation in the 3'sequence of miR-146a (miR146a 3'F). They reasoned that, if such 3' sequence is necessary for the miRNA activity, then mice harboring such mutation (3'F mice) should show altered target repression and, possibly, a phenotype. After careful phenotypic analysis, the 3'F mutants did not show phenotypic alterations and instead resembled wild type mice. This was in contrast to miR-146a KO mice, which show strong immune defects (such as splenomegaly and LPS hypersensitivity). Therefore, the authors conclude that the 3' pairing of such miRNA is dispensable.
Major Points: The comprehensive phenotypic analysis, which reveals wild type appearance of the 3'F mice, strongly suggests that miR-146a represses its targets only through the seed sequence. However, a convincing connection between the miRNA loss (already in the KO) and the observed phenotype is missing, thus I am not fully convinced that the results presented are conclusive. In fact, although the miR-146a KO mice show a strong phenotype, their pathology cannot be definitely connected to loss of miRNA activity (ie. via target mRNA de-repression). For the miRNA to be convincingly connected to the immune defects described in miR-146a KO mice here and in (Boldin, 2011) , a rescue experiment (suppression of phenotype by exogenously providing miR-146a in KO mice), analysis of mutant mice carrying a miR-146a with scrambled seed sequence (which should show similar pathology as KO), or of mice carrying mutations in the putative miR-146a targets would have been helpful. For these reasons, I fear that this miRNA is not the best model for the hypothesis (importance of 3'pairing) being tested. I agree that the 3'F mice seem similar to wild type and thus the 3' pairing might be dispensable, but how can we mechanistically connect the altered 3' pairing to miRNA activity if there are no obvious direct targets to study? 2. If we embrace the hypothesis that miR-146a works only through few targets (irak1?), thus explaining the lack of global change in transcripts in KO mice (discussed above), then I would want to see a functional validation of such targets (e.g. miRNA binding site manipulations). Presence of seed match is not direct evidence of miRNA-dependent repression. 3. Boldin et al, had described irak1 and traf6 as bona fide target, whose protein level was affected by miR-146a deletion. However, Bertolet and colleagues cannot reproduce the traf6 misregulation. Could the authors comment on this discrepancy? 4. Experiments carried out in vitro (Suppl. Fig.2) show that the 3'pairing has a function in target repression, as acknowledged by the authors in the first result paragraph. What is the authors' opinion about the fact that the same behavior is not observed in vivo?
Minor notes: 1. The same histological section corresponding to the 3'F mouse is present in three different panels: Fig2J (the same image is shown as both liver and kidney) and in Fig.3D , which describes older mice. Fig. 7 : the authors should comment on which kind of control they used for the luc assay. 8. Fig. 7 : Do the targets have a seed match only or also 3'pairing? You would not expect any change in targets with a seed match between WT and 3'F mice. If a change has to be seen, it would be in targets with 3'pairing to the wt miR-146a. 9. Consider putting together S1A and S2B-C and S1B-C with S2D-E for immediate visualization of miRNA/target duplex in each luc assay. Please add stats on the plots. 10. In general, please add stats to all figures and plots where appropriate and make homogeneous axis labels (e.g. S3).
Reviewer #3 (Comments to the Authors (Required)):
Review of MS. LSA-2018-00249 In the manuscript entitled: MiR-146a wild-type 3' sequence identity is dispensable for proper innate immune function in vivo' the authors perform experiments with newly created miR-146a knockout mice that for the most part recapitulate phenotypes of the immune system that have previously been published. Additionally, miR-146a3'F mice were generated, designed to reduce 3' sequence complementarity with target mRNAs, while at the same time leaving the miR-146a seed sequence unaltered. Extensive and carefully conducted experiments show that these mice in some instances are mildly hypomorphic, but in most aspects are indistinguishable from the wild-type phenotype.
Major points: 1. The authors neglect to mention that miR-146a and miR-146b share the same seed sequence and only differ by two nucleotides in their 3' sequences. At no point do they mention that miR-146b could potentially replace the function of miR-146a3'F. Mild hypomorphic phenotypes might reflect a mixture of miR-146b and miR-146a3'F activity. For unknown reasons, the complete lack of miR146a in miR-146a-deficient mice might be harder to compensate by miR-146b. In general I wonder why the authors chose miR-146a over for instance miR-155, which is not part of a miRNA family. The authors should measure and state the miR-146b levels in Figures 1 G-I and 6 A. They need to discuss the possibility of miR-146b compensating for miR-146a3'F and (in Figure 6 A-B) miR-146a function.
2. Although I value the large body of negative data proving that the 3' part of miR-146a does not impact on mouse phenotypes, I don't think the analysis of mRNA and protein expression --as it is --is very useful to the readers. It seems that the phenotypic difference between WT, miR-146a3'F compared to KO is not reflected in the transcriptome or proteome of BMDM cells, and either the choice of cells confounds to demonstrate it or other miRNAs or RNA-binding proteins compensate in these cells and under these culture conditions. To improve the presentation the isolation and profiling of myeloid cells from the animals without in vitro culture should be performed to demonstrate valid differences or, alternatively, the nature of compensation should be demonstrated by anti-Ago-IP/Immunoprecipitation or even CLIP-Seq technology.
Minor points: Suppl. Fig. 2 is presented before Suppl. Fig. 1 in the text. All panels showing alignments should be presented in Suppl. Fig. 1 to avoid this and to make it easier for the reader.
Experiments of Suppl. Fig. 2 would be more convincing if miR-146a and miR-146a3'F had to undergo intracellular processing as pri-or pre-miRNAs.
There are few typos (for example page 8, Results mir-146a3'/-should read miR-1463'F/-or page 11, Discussion, line 4: 'miR-46a' should read 'miR-146a').
1st Authors' Response to Reviewers: January 15, 2019
We are grateful to the referees for their time, their thoughtful and generally positive and/or constructive reviews of the manuscript, and the issues that they raise to help us improve our final product. Please find point-by-point responses to these issues below.
In this manuscript, G. Bertolet and colleagues investigate the functional consequences of mutating the 3´-most sequence of miR-146a, without changing the seed nor the central region. Because conflicting data has been published regarding the contribution of non-seed regions, it is indeed important to probe the consequences of such a mutation (especially when the tested phenotypes include in vivo, integrated readouts, as is the case here). The authors find that the mutation triggers some consequences at the microscopic level (when the readout is a target RNA or protein abundance), but they did not find any convincing proof for macroscopic consequences. This is an interesting manuscript, addressing an important question in the field of miRNA-mediated gene regulation. The detailed phenotypic assessment (including many physiological assays, interrogating both homozygous and hemizygous mutants) is exemplary. Several problems (two major points, which seem to affect the authors' interpretations; but also many minor points, which make the manuscript obscure or inconsistent on a few important issues) tend to weaken its conclusions, so I recommend correcting all these points. Once this is done, the manuscript will be a strong candidate for publication in Life Science Alliance. Fig. 1A does not support such a conclusion. It is not exactly clear to me what the authors mean with "similarly processed". Do they imply that the mutant miRNA is matured from Drosha and Dicer cleavages occurring at the same positions? If yes, that poorly-resolved Northern blot, showing smeary bands on two distinct membranes (none of them containing a size marker), does not provide enough information on miRNA length to conclude anything (not even mentioning the fact that miRNAs can have the same length but not the same 5´ and 3´ ends). Or do the authors mean that the mutant miRNA accumulates at the same level than the wt miRNA? If yes, these two membranes, hybridized with two different probes, are also useless for such a conclusion. It is actually possible to use Nothern blot for such an assessment, but then each membrane has to be calibrated with synthetic RNA oligos in a few additional lanes, in order to convert Northern blot intensity signals into fmol of RNA (apparently Fig. 1G used calibrating synthetic oligos: these very same oligos could be used to make a Northern blot really quantitative for Fig. 1A ).
We agree with the reviewer that the presentation of this figure could Figure 3 , and supporting source data files) that confirms that the predicted mutant miRNA is produced. These latter data are mentioned at the top of page 7 and further explained in detail below, in response to a concern raised by Reviewer #3.
2. Page 28: Fig. 1H compares WT to 3´F in the left panel, and WT to KO in the right panel. Why are the WT histograms so different between the two panels? This is not just a normalization issue, because even the ratios between samples are clearly different (e.g., compare thymus to spleen in both panels). It may be that the PCR-based quantification is not that precise (that would be perfectly understandable), or that there is a lot of biological variability between the batches of mice. But then, why are the s.e.m. so narrow? Whether there is a lot of technical noise, or a lot of biological variability, this should also reflect in the s.e.m. error bars... In the end, if WT replicates are so poorly reproducible, then the whole assay may not be able to detect efficiently any potential difference between WT and 3´F miRNAs. Figure 1I was generated after Figure 1H Another phenomenon seems to explain equally well the conservation of non-seed sequences: because miRNA*s seem to be under a selective pressure to repress seed-matched transcripts (see https://www.ncbi.nlm.nih.gov/pubmed/21177881). As the pre-miRNA secondary structure (hairpin-shaped) is also conserved, then the miRNA sequence facing the miRNA* seed has to be conserved -implying that the miRNA 3´ end should be conserved even if it did not play any function in miRNA target recognition. This is indeed a tantalizing and plausible possibility. However, our goal in this study was not to explain the evolutionary conservation of non-seed sequences per se, but rather, to evaluate one specific hypothesis (i.e. miRNA target recognition and/or function) as to why such conservation exists. As such, we feel that bringing up an alternative hypothesis -one which none of our experiments even approach addressing -would be distracting to our readers.
Given the amount of labor that was required to generate each of these subpanels, the comparisons in the experiments depicted in Figures 1H and 1I were run on different mice, on different days, and on different freshly prepared quantitation standards. As such, the disparities are likely derived from both biological and technical variability (for example partial degradation of the standard in a freeze/thaw cycle -
3. Page 4: for the sake of clarity, the sequence of wild-type and 3´F miR-146a should be given in a main figure (they are currently given in supplementary figure 2, which does not make it easy for the reader to see them while reading the manuscript). Figure 1B . However, the font we used was admittedly small, and so we can see how it could have easily been missed or unreadable. As such, we have enlarged the font. Thank you for pointing this out.
The sequence of both alleles was indeed present in
Also: the justification of the choice of the mutant sequence (nt 13-20 being AAGUGUCC instead of UCCAUGGG) is very obscure (what is an "anti-complementary sequence"? I know what a "complementary sequence" is, I know what an "antisense sequence" is -and these are the same thing; but an "anti-complementary sequence" is very mysterious to me; at least I can see that it is not the complementary sequence of the wild-type 13-20 subsequence). Please detail.
We apologize for the less than ideal choice of words on our part. This has been rectified. Fig. 1H shows some large differences in wt vs. mutant miRNA abundance in at least two samples (kidney and CD8+), so the text should read "in most tissues and cell populations examined", not "all tissues and cell populations".
We have made this change.
5. Page 7, sentence "However, none of these phenotypes [...]": please define "aged" mice (the next sentence clearly defines what an "extremely advanced age" is: please do the same here). This is a good point. We have taken out the adjective "aged" and replaced it with "age-matched" here.
6. Page 10, sentence "Because RNA-interference in mammals can mediate [...]". I know there is sometimes much confusion about that term in the literature, but note that "RNA interference" is different from the "miRNA pathway". RNA interference is a sequence-specific repression triggered by a double-stranded RNA (which is converted into siRNAs by Dicer). Fig. 1E : maybe it's just an image resolution issue, but: I can't see a WT band for the "miR-146a +/3´F lane" (second from last), while I was expecting one. Anything wrong with that sample?
The band is clearly visible to us in the submitted files. However, we have altered the contrast if this image in the hope that the band will be more clearly visible. Thank you for pointing out the difficulty some people might have had in seeing this.
9. Page 28, Fig. 1D : how can we be sure that the band shown with an asterisk is really due to cross-hybridization? If there is no argument supporting it, it should be flagged as "probable" cross-hybridizing band.
The argument is that, given that the probe lies entirely within the 8 kb fragment that will result from EcoRV/BamHI double digestion, that 8 kb fragment is clearly present on the gel (the same rationale exists for the 5.1 kb fragment resulting from introduction of the EcoRV site from the targeting vector -the probe does not span this junction), by definition the ~5.4 kb band that is present must represent hybridization of the probe to a genomic fragment from elsewhere in the genome. This argument is strengthened given that (i) the band in question was present in all ES cell clones examined in this Southern Blot, arguing strongly against non-targeted insertion of a the targeting vector as a transgene, which would be expected to occur randomly, (ii) partial digestion of any of the predicted fragments that we are assaying for is not predicted to yield this ~5.4 kb band, and (iii) the mobility of the band is not affected by the homologous recombination.
We have clarified our explanation of how these data were analyzed.
Thank you for pointing this out. It was indeed confusing. The controls are the very same constructs used in what is now Supplemental Fig S1, and this is now noted in the revised figure legend for this figure.
Major Points:
The comprehensive phenotypic analysis, which reveals wild type appearance of the 3'F mice, strongly suggests that miR-146a represses its targets only through the seed sequence. However, a convincing connection between the miRNA loss (already in the KO) and the observed phenotype is missing, thus I am not fully convinced that the results presented are conclusive. In fact, although the miR-146a KO mice show a strong phenotype, their pathology cannot be definitely connected to loss of miRNA activity (ie. via target mRNA de-repression). For the miRNA to be convincingly connected to the immune defects described in miR-146a KO mice here and in (Boldin, 2011), a rescue experiment (suppression of phenotype by exogenously providing miR-146a in KO mice), analysis of mutant mice carrying a miR-146a with scrambled seed sequence (which should show similar pathology as KO), or of mice carrying mutations in the putative miR-146a targets would have been helpful. For these reasons, I fear that this miRNA is not the best model for the hypothesis (importance of 3'pairing) being tested.
With all of our respect, we are confused by the reviewer's line of logic. Any pathology/ phenotype observed within the context of a defined genetic lesion is, by convention, defined as a product of that genetic lesion. This is the case whether in an animal or in an isolated cell type, both of which we have examined here. The rescue experiments proposed are done in this context with alleles -both the wild-type or the 3'F allele demonstrably offset the phenotype and pathology associated with miR-146a loss-of-function. Indeed, this offset can be assumed to be a product of correct temporal and spatial expression, and expression at physiological levels given that the rescue is provided as a "knock-in" to the endogenous locus. It is unclear to us what the benefits of providing miR-146a in another fashion might be. While we agree that an allele of miR-146a with a scrambled seed would be interesting, as would germline manipulations of established miR-146a targets, such experiments are not trivial and are beyond the scope of this work.
1. There are no global changes in transcripts and proteins in miR-146a 3'F. However, there are no changes in the KO mice either, and this was already suggested in the previous publication describing miR-146a KO mice (Boldin 2011). I agree that the 3'F mice seem similar to wild type and thus the 3' pairing might be dispensable, but how can we mechanistically connect the altered 3' pairing to miRNA activity if there are no obvious direct targets to study?
Our work is an in vivo analysis to determine whether miR-146a 3' sequence identity (and thuspresumably -pairing miR-146a in LPS-stimulated B cells (Jiang et al., 2018) , and in the PBMCs of patients with Sjögren's syndrome (in which miR-146a levels are elevated), Traf6 levels are also abnormally high when compared to healthy controls (Zilahi et al., 2012) . This has been added to the discussion. . Fig.2) show that the 3' pairing has a function in target repression, as acknowledged by the authors in the first result paragraph. What is the authors' opinion about the fact that the same behavior is not observed in vivo?
Experiments carried out in vitro (Suppl
Most simply put, we feel that the discrepancy between our in vitro and in vivo results is a reflection on the limitation of in vitro reporter/validation systems, and what may be drawn from them. We do note that siRNA "off-target" phenomena and spectra are well-established in the literature, and while the spectrum of putative targets for a given miRNA is computationally defined in part by evolutionary conservation of seed-complementary sequences within these targets, the spectrum of "off-target" transcripts is defined solely by the presence of an appropriate seed-match and response to the presence of the small RNA species provided, with no requirement for conservation. Ergo, it seems reasonable to infer that responses of certain 3' UTR reporters to an exogenously provided miRNA in vitro may exaggerate a corresponding physiological regulatory relationship. However, given the myriad of other possibilities (e.g. native versus reporter sequence identity, protein association, etc.), the controversy that continues to surround miRNA target recognition and biological function, and what we feel we can confidently draw from our profiling data, we feel it is most wise to limit our speculation on this point within the manuscript itself.
Minor notes:
1. The same histological section corresponding to the 3'F mouse is present in three different panels: Fig2J (the same image is shown as both liver and kidney) and in Fig.3D , which describes older mice.
That is horrifying. Please accept our most sincere apologies and thank you so much for noticing this. The reviewers have our sincere thanks for bringing this study, which is now cited in the introduction, to our attention.
3. I would move the results shown in S2 to the main text and move Fig.4 to Suppl.
We can see the merit in this idea, but we hope that the reviewer will recognize the merit of our own existing choice of presentation here.
Figure 1A is mislabeled. (What is the control?)
The labeling for Figure 1A was indeed incorrect. Given this, and concerns raised by Reviewer 1, we have replaced the figure with another iteration of the experiment that is more appropriately labeled and altered our statement of the conclusions that can be drawn from the figure. Thank you. The reviewer is correct. Thank you for pointing out the lack of detail. The figure legend has been updated to rectify this. 7. Fig. 7 : the authors should comment on which kind of control they used for the luc assay.
Thank you for catching that. We apologize for the omission. 8. Fig. 7 : Do the targets have a seed match only or also 3'pairing? You would not expect any change in targets with a seed match between WT and 3'F mice. If a change has to be seen, it would be in targets with 3'pairing to the wt miR-146a. Figure 7 were based on the criteria of (i) having a canonical seed match, and (ii) exhibiting differences in relative expression that would be consistent with a difference in regulation among the three alleles evaluated. Predicted 3' pairing was not a criterium for classification. Nonetheless, alignments of the miRNAs with each of these potential targets are now provided in a new supplementary figure. 9. Consider putting together S1A and S2B-C and S1B-C with S2D-E for immediate visualization of miRNA/target duplex in each luc assay. Please add stats on the plots.
The targets within
We agree that this would facilitate comprehension of the figures, and they have been altered accordingly.
10. In general, please add stats to all figures and plots where appropriate and make homogeneous axis labels (e.g. S3). Figure S3 .
At the reviewer's request, we have carefully surveyed our figures and plots to add any missing statistics and have improved the homogeneity of axis labels in
Major points: 1. The authors neglect to mention that miR-146a and miR-146b share the same seed sequence and only differ by two nucleotides in their 3' sequences. At no point do they mention that miR146b could potentially replace the function of miR-146a3'F. Mild hypomorphic phenotypes might reflect a mixture of miR-146b and miR-146a3'F activity. For unknown reasons, the complete lack of miR-146a in miR-146a-deficient mice might be harder to compensate by miR-146b. Ultimately then, the point that we are trying to make is that because the qRT-PCR methodology used to provide the data in Figure 1H is ligation-independent, and because these data are calculated from a dilution of a synthetic standard in total RNA from D. melanogaster (which does not encode miR-146 family members), it is a far more accurate quantitation of absolute expression of miR-146a3'F within the BMDMs than ligation-dependent small RNA sequencing data.
They need to discuss the possibility of miR-146b compensating for miR-146a3'F and (in Figure  6 A-B) miR-146a function.
A discussion of this, following the rationale that we provide above, is now included in the discussion.
2. Although I value the large body of negative data proving that the 3' part of miR-146a does not impact on mouse phenotypes, I don't think the analysis of mRNA and protein expression --as it is --is very useful to the readers. It seems that the phenotypic difference between WT, miR146a3'F compared to KO is not reflected in the transcriptome or proteome of BMDM cells, and either the choice of cells confounds to demonstrate it or other miRNAs or RNA-binding proteins compensate in these cells and under these culture conditions. To improve the presentation the isolation and profiling of myeloid cells from the animals without in vitro culture should be performed to demonstrate valid differences or, alternatively, the nature of compensation should be demonstrated by anti-Ago-IP/Immunoprecipitation or even CLIP-Seq technology. Minor points: Suppl. Fig. 2 is presented before Suppl. Fig. 1 in the text. All panels showing alignments should be presented in Suppl. Fig. 1 to avoid this and to make it easier for the reader.
We have re-assigned different subfigures between Fig S1 and S2 to facilitate viewing, in keeping with the comments of multiple reviewers.
The reviewer's point is well taken, and we can see the merit in this notion. Our intention here, however, was to test the function of the mature miRNA in a fashion that exclude any differences that might arise from altered efficiency in precursor processing or loading.
We have corrected all of these that we have found, including the ones brought to our attention here. Thank you very much. Thank you for submitting your revised manuscript entitled "MiR-146a wild-type 3' sequence identity is dispensable for proper innate immune function in vivo". As you will see, reviewer #1 re-evaluated your work again and now supports publication of a slightly further revised version of your manuscript in Life Science Alliance. I would thus like to invite you to address the minor comments made by the reviewer and to submit a final version to us. Please also address the following points when revising your work:
-please add a callout to figure panel 2K, S2E and S2F in the manuscript text -please add a label for figure panel 3H in figure 3 -please add a 'C' to the figure legend for SFig5 -please add error bar descriptions in all figure legends, a few are currently missing (eg. for panels in Fig 1, 5, 7) To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information.
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